Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · July 19, 2024

Triple negative breast cancer

Bhaskara Reddy Madhira

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Laura Nadeau

    Jul 20, 2024

    If Pet and mri were negative I would not add Xeloda.  If she has residual evidence of disease, would consider repeat biopsy for NGS.  She should also have genetic testing as Parp-I would be reasonable if she is HMR deficient.  Surveillance with CTCs and q6 month imaging with alternating MRI and  mammogram is how I would follow.  

  • Nov 03, 2024

    Pending Moderator approval.
    Delete

Further Reading